YAP1 and cancer: While we do not have outcome data for our patients, it is noteworthy that meta-analysis has shown that overexpression of YAP-1 is significantly associated with poorer prognosis and promotes resistance to therapy in patients with various cancers, including SCCs (68, 83), making it a valuable biomarker for predicting prognosis in cancer patients.